儿童大环内酯类耐药肺炎支原体肺炎诊疗理念与实践

doi:10.12372/jcp.2024.24e0003

摘要/Abstract

摘要：

2023年7月以来我国乃至全球迎来了肺炎支原体肺炎的流行高峰，给儿童健康、家庭及社会均带来了沉重的负担。尽管大环内酯类抗菌药物为指南推荐的首选用药，本次流行的肺炎支原体肺炎住院患儿中，以大环内酯类耐药为主。这对传统的诊疗模式带来了巨大的挑战，特别是肺动脉栓塞病例的增多，需要临床医师思考并实践新的诊疗理念。

关键词: 肺炎支原体肺炎, 大环内酯类耐药, 肺动脉栓塞

Abstract:

Since July 2023, China and even the world have experienced a peak outbreak of Mycoplasma pneumoniae pneumonia, which has brought a heavy burden to children's health, families, and society. Although macrolide antibiotics are the first choice recommended by the guidelines, the majority of hospitalized children with Mycoplasma pneumoniae pneumonia in this epidemic are resistant to macrolides. This has brought great challenges to the traditional diagnosis and treatment model, especially the increasing number of pulmonary embolism cases, which requires clinicians to think about and practice new diagnosis and treatment concepts.

Key words: Mycoplasma pneumoniae pneumonia, macrolide-resistant, pulmonary embolism

殷勇, 陈健德. 儿童大环内酯类耐药肺炎支原体肺炎诊疗理念与实践[J]. 临床儿科杂志, 2024, 42(3): 177-181.

YIN Yong, CHEN Jiande. Diagnosis and treatment philosophy and practice of macrolide-resistant Mycoplasma pneumoniae pneumonia in children[J]. Journal of Clinical Pediatrics, 2024, 42(3): 177-181.

参考文献 41

[1]	Chen J, Yin Y, Zhao L, et al. Mycoplasma pneumoniae infection prediction model for hospitalized community-acquired pneumonia children[J]. Pediatr Pulmonol, 2021, 56(12): 4020-4028. doi: 10.1002/ppul.v56.12
[2]	Baer G, Engelcke G, Abele-Horn M, et al. Role of Chlamydia pneumoniae and Mycoplasma pneumoniae as causative agents of community-acquired pneumonia in hospitalised children and adolescents[J]. Eur J Clin Microbiol Infect Dis, 2003, 22(12): 742-745. doi: 10.1007/s10096-003-1037-9
[3]	中华人民共和国国家卫生健康委员会. 儿童肺炎支原体肺炎诊疗指南(2023年版)[J]. 中国合理用药探索, 2023, 20(3): 16-24.
[4]	Xiao L, Ptacek T, Osborne JD, et al. Comparative genome analysis of Mycoplasma pneumoniae[J]. BMC Genomics, 2015, 16(1): 610. doi: 10.1186/s12864-015-1801-0
[5]	Zhang WZ, Zhang SJ, Wang QY, et al. Outbreak of macrolide-resistant Mycoplasma pneumoniae in a primary school in Beijing, China in 2018[J]. BMC Infect Dis, 2019, 19(1): 871. doi: 10.1186/s12879-019-4473-6
[6]	Leng M, Yang J, Zhou J. The molecular characteristics, diagnosis, and treatment of macrolide-resistant Mycoplasma pneumoniae in children[J]. Front Pediatr, 2023, 11: 1115009. doi: 10.3389/fped.2023.1115009
[7]	Razin S, Yogev D, Naot Y. Molecular biology and pathogenicity of mycoplasmas[J]. Microbiol Mol Biol Rev, 1998, 62(4): 1094-1156. doi: 10.1128/MMBR.62.4.1094-1156.1998
[8]	Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the respiratory tract and beyond[J]. Clin Microbiol Rev, 2017, 30(3): 747-809. doi: 10.1128/CMR.00114-16 pmid: 28539503
[9]	Chen J, Zhang J, Lu Z, et al. Mycoplasma pneumoniae among Chinese outpatient children with mild respiratory tract infections during the coronavirus disease 2019 pandemic[J]. Microbiol Spectr, 2022, 10(1): e0155021. doi: 10.1128/spectrum.01550-21
[10]	Oishi T, Ouchi K. Recent trends in the epidemiology, diagnosis, and treatment of macrolide-resistant Mycoplasma pneumoniae[J]. J Clin Med, 2022, 11(7): 1782. doi: 10.3390/jcm11071782
[11]	Han X, Li S, Lu S, et al. Amplification of 16S rDNA by nested PCR for measurement of Mycoplasma pneumoniae DNA over time: clinical application[J]. J Med Microbiol, 2012, 61(Pt 3): 426-430. doi: 10.1099/jmm.0.030098-0
[12]	Nilsson AC, Björkman P, Persson K. Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection[J]. BMC Microbiol, 2008, 8: 93. doi: 10.1186/1471-2180-8-93 pmid: 18547431
[13]	Chen J, Ji F, Yin Y, et al. Time to Mycoplasma pneumoniae RNA clearance for wheezy vs. non-wheezy young children with community-acquired pneumonia[J]. J Trop Pediatr, 2021, 67(1): fmaa109. doi: 10.1093/tropej/fmaa109
[14]	Suzuki Y, Shimotai Y, Itagaki T, et al. Development of macrolide resistance-associated mutations after macrolide treatment in children infected with Mycoplasma pneumoniae[J]. J Med Microbiol, 2017, 66(11): 1531-1538. doi: 10.1099/jmm.0.000582 pmid: 28984229
[15]	Zhao F, Li J, Liu J, et al. Antimicrobial susceptibility and molecular characteristics of Mycoplasma pneumoniae isolates across different regions of China[J]. Antimicrob Resist Infect Control, 2019, 8: 143. doi: 10.1186/s13756-019-0576-5
[16]	Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae[J]. Front Microbiol, 2016, 7: 693. doi: 10.3389/fmicb.2016.00693 pmid: 27242718
[17]	Lin K, Zahlanie Y, Ortwine JK, et al. Decreased outpatient fluoroquinolone prescribing using a multimodal antimicrobial stewardship initiative[J]. Open Forum Infect Dis, 2020, 7(6): ofaa182. doi: 10.1093/ofid/ofaa182
[18]	Chen J, Qi X, Yin Y, et al. Effects of minocycline on macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children: a single-center retrospective study[J]. Transl Pediatr, 2021, 10(11): 2997-3004. doi: 10.21037/tp
[19]	Okada T, Morozumi M, Tajima T, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children Clin Infect Dis, 2012, 55(12): 1642-1649.
[20]	Volovitz B, Shkap R, Amir J, et al. Absence of tooth staining with doxycycline treatment in young children[J]. Clin Pediatr (Phila), 2007, 46(2): 121-126. doi: 10.1177/0009922806290026
[21]	Fernald GW. Immunologic mechanisms suggested in the association of M. pneumoniae infection and extrapulmonary disease: a review[J]. Yale J Biol Med, 1983, 56(5-6): 475-479.
[22]	Izumikawa K. Clinical features of severe or fatal Mycoplasma pneumoniae pneumonia[J]. Front Microbiol, 2016, 7: 800. doi: 10.3389/fmicb.2016.00800 pmid: 27313568
[23]	Taves MD, Ashwell JD. Glucocorticoids in T cell deve-lopment, differentiation and function[J]. Nat Rev Immunol, 2021, 21(4): 233-243. doi: 10.1038/s41577-020-00464-0
[24]	Sendi P, Graber P, Lepère F, et al. Mycoplasma pneumoniae infection complicated by severe mucocutaneous lesions[J]. Lancet Infect Dis, 2008, 8(4): 268. doi: 10.1016/S1473-3099(08)70068-9
[25]	You SY, Jwa HJ, Yang EA, et al. Effects of methyl-prednisolone pulse therapy on refractory Mycoplasma pneumoniae pneumonia in children[J]. Allergy Asthma Immunol Res, 2014, 6(1): 22-26. doi: 10.4168/aair.2014.6.1.22
[26]	Sun LL, Ye C, Zhou YL, et al. Meta-analysis of the clinical efficacy and safety of high- and low-dose methylprednisolone in the treatment of children with severe Mycoplasma pneumoniae pneumonia[J]. Pediatr Infect Dis J, 2020, 39(3): 177-183. doi: 10.1097/INF.0000000000002529
[27]	Wu X, Lu W, Wang T, et al. Optimization strategy for the early timing of bronchoalveolar lavage treatment for children with severe Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2023, 23(1): 661. doi: 10.1186/s12879-023-08619-9
[28]	Patrucco F, Failla G, Ferrari G, et al. Bronchoscopy during COVID-19 pandemic, ventilatory strategies and procedure measures[J]. Panminerva Med, 2021, 63(4): 529-538. doi: 10.23736/S0031-0808.21.04533-X pmid: 34606187
[29]	Zhou Y, Wang J, Chen W, et al. Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2020, 20(1): 633. doi: 10.1186/s12879-020-05356-1
[30]	Liu J, He R, Wu R, et al. Mycoplasma pneumoniae pneumonia associated thrombosis at Beijing children's hospital[J]. BMC Infect Dis, 2020, 20(1): 51. doi: 10.1186/s12879-020-4774-9
[31]	Chen S, Ding Y, Vinturache A, et al. Pulmonary embolism associated with mycoplasma in a child[J]. Lancet Infect Dis, 2020, 20(11): 1347. doi: 10.1016/S1473-3099(20)30253-X pmid: 33098782
[32]	Rajpurkar M, Biss T, Amankwah EK, et al. Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics. A systematic review[J]. Thromb Haemost, 2017, 117(6): 1199-1207. doi: 10.1160/TH16-07-0529
[33]	Song S, Xu Y. A retrospective study of the clinical characteristics of 9 children with pulmonary embolism associated with Mycoplasma pneumoniae pneumonia[J]. BMC Pediatr, 2023, 23(1): 370. doi: 10.1186/s12887-023-04188-7
[34]	Witmer CM, Steenhoff AP, Shah SS, et al. Mycoplasma pneumoniae, splenic infarct, and transient antiphospholipid antibodies: a new association?[J]. Pediatrics, 2007, 119(1): e292-e295. doi: 10.1542/peds.2006-1340 pmid: 17178923
[35]	Snowden N, Wilson PB, Longson M, et al. Antiphospholipid antibodies and Mycoplasma pneumoniae infection[J]. Postgrad Med J, 1990, 66(775): 356-362. pmid: 2371184
[36]	Han C, Zhang T, Zheng J, et al. Analysis of the risk factors and clinical features of Mycoplasma pneumoniae pneumonia with embolism in children: a retrospective study[J]. Ital J Pediatr, 2022, 48(1): 153. doi: 10.1186/s13052-022-01344-0
[37]	Moore AJE, Wachsmann J, Chamarthy MR, et al. Imaging of acute pulmonary embolism: an update[J]. Cardiovasc Diagn Ther, 2018, 8(3): 225-243. doi: 10.21037/cdt
[38]	Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism[J]. Blood Adv, 2020, 4(19): 4693-4738. doi: 10.1182/bloodadvances.2020001830 pmid: 33007077
[39]	Fu Y, Zhang TQ, Dong CJ, et al. Clinical characteristics of 14 pediatric Mycoplasma pneumoniae pneumonia associated thrombosis: a retrospective study[J]. BMC Cardiovasc Disord, 2023, 23(1): 1. doi: 10.1186/s12872-022-03030-9
[40]	Chen L, Yin J, Liu X, et al. Thromboembolic complications of Mycoplasma pneumoniae pneumonia in children[J]. Clin Respir J, 2023, 17(3): 187-196. doi: 10.1111/crj.v17.3
[41]	Sheng CQ, Yang CF, Ao Y, et al. Mycoplasma pneumoniae pneumonia with pulmonary embolism: a study on pediatric cases in Jilin province of China[J]. Exp Ther Med, 2021, 21(3): 201. doi: 10.3892/etm